enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate Update
27.10.2022 - - Ended the quarter with $42.7 million in cash and investments- Burn rate of $4.5 million for the quarter- Runway extends through the end of 2024 including release of SAVVE topline pivotal trial data and initiation of TAVVE first in human ... Seite 1